1 MG | x |
Save $ 7.00 |
$ 125.00
|
10 MG | x |
Save $ 53.00 |
$ 1,005.00
|
Chemical Properties of 'Erlotinib D6' |
|
CAT No. : |
CS-O-03064 |
CAS Registry No. : | 1034651-23-4 |
Category : | Isotope Labelled Compounds |
Molecular Weight: | 399.47 |
Molecular Formula : | C₂₂H₁₇D₆N₃O₄ |
OTHER INFORMATION of 'Erlotinib D6' |
|
Purity : | Not less than 95 % |
Therapeutic : | Anti-Cancer / Oncology |
Isotopic Enrichment : | Not less than 98 % |
Purity : | Not less than 95 % |
Therapeutic : | Anti-Cancer / Oncology |
Isotopic Enrichment : | Not less than 98 % |
Applicationnotes : | "Labelled Erlotinib. Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.;Labeled Erlotinib, intended for use as an internal standard for the quantification of Erlotinib by GC- or LC-mass spectrometry." |
Synonym : | Not available |
References : | "Moyer; J,D,; et al,: Cancer Res,; 57; 4838 (1997); Hidalgo; M,; et al,: J, Clin, Oncol,; 19; 3267 (2001); Perez-Soler; R,; et al,: J, Clin, Oncol,; 22; 3238 (2004); Blackhall; F,H,; et al,: Expert Opin, Pharmacother,; 6; 995 (2005);" |
Smileys : | C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC([2H])([2H])[2H])=C3)OCCOC([2H])([2H])[2H])=C1 |
Appearance : | White to off white solid |
Custom Duty : | Applicable |
Port of Loading : | Canada |
Expected Dispatch : | 15-Aug-2022 |
Taxes : | Not Applicable |
Refund Policy : | 30-days money back |
Custom Duty : | Applicable |
Port of Loading : | Canada |
Expected Dispatch : | 15-Aug-2022 |
Taxes : | Not Applicable |
Refund Policy : | 30-days money back |
Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) \u2014 either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation \u2014 which has spread to other parts of the body. It is taken by mouth.
Common side effects include rash, diarrhea, muscle pain, joint pain, and cough. Serious side effects may include lung problems, kidney problems, liver failure, gastrointestinal perforation, stroke, and corneal ulceration. Use in pregnancy may harm the baby. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
Erlotinib was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.
Looking for a discounted price or need more info for 'Erlotinib D6 (CS-O-03064)' ?
If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.